Scarica l'app Stockscreener
54.35
2.49%
-1.39
Dopo l'orario di chiusura:
54.80
0.45
+0.83%
Precedente Chiudi:
$55.74
Aprire:
$55.61
Volume 24 ore:
113.03K
Relative Volume:
1.50
Capitalizzazione di mercato:
$156.20M
Reddito:
$697.00K
Utile/perdita netta:
$-37.19M
Rapporto P/E:
-1.4418
EPS:
-37.6952
Flusso di cassa netto:
$-29.34M
1 W Prestazione:
-5.82%
1M Prestazione:
+17.64%
6M Prestazione:
-13.44%
1 anno Prestazione:
-90.00%
Intervallo 1D:
$54.03
$57.50
Intervallo di 1 settimana:
$54.03
$60.51
Portata 52W:
$7.26
$240.00
Spruce Biosciences Inc Stock (SPRB) Company Profile
Nome
Spruce Biosciences Inc
Settore
Industria
Telefono
(415) 655-4168
Indirizzo
611 GATEWAY BOULEVARD, SUITE 740, SOUTH SAN FRANCISCO
Compare SPRB vs VRTX, REGN, ARGX, MRNA, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
SPRB
Spruce Biosciences Inc
|
54.35 | 160.20M | 697.00K | -37.19M | -29.34M | -37.70 |
VRTX
Vertex Pharmaceuticals Inc
|
514.56 | 132.08B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
793.26 | 83.15B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
984.04 | 62.71B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
136.62 | 54.14B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
203.35 | 44.51B | 742.00K | -1.37B | -1.07B | -7.0731 |
Spruce Biosciences Inc Stock (SPRB) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-04-27 | Iniziato | Craig Hallum | Buy |
| 2025-12-23 | Iniziato | Oppenheimer | Outperform |
| 2025-12-03 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2025-10-28 | Aggiornamento | Citizens JMP | Mkt Perform → Mkt Outperform |
| 2024-12-11 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| 2024-12-11 | Downgrade | Oppenheimer | Outperform → Perform |
| 2024-03-14 | Downgrade | Guggenheim | Buy → Neutral |
| 2024-03-14 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2024-03-14 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| 2024-03-14 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2024-03-14 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-02-21 | Iniziato | Guggenheim | Buy |
| 2021-12-17 | Iniziato | Oppenheimer | Outperform |
| 2021-12-10 | Iniziato | The Benchmark Company | Speculative Buy |
| 2021-11-16 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2021-07-19 | Iniziato | H.C. Wainwright | Buy |
| 2021-04-26 | Ripresa | Credit Suisse | Outperform |
| 2020-11-03 | Iniziato | Cowen | Outperform |
| 2020-11-03 | Iniziato | Credit Suisse | Outperform |
| 2020-11-03 | Iniziato | RBC Capital Mkts | Outperform |
| 2020-11-03 | Iniziato | SVB Leerink | Outperform |
Mostra tutto
Spruce Biosciences Inc Borsa (SPRB) Ultime notizie
Spruce Biosciences to Participate in the H.C. Wainwright 28th Annual Global Investment Conference - BioSpace
Spruce Biosciences CEO will speak in New York on Sept. 15 - stocktitan.net
Guggenheim initiates coverage on Spruce Biosciences with Buy rating - scanx.trade
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Why is Spruce Biosciences stock gaining 4% today? By Investing.com - Investing.com Canada
Spruce Biosciences stock gains after analyst backs regulatory progress - Yahoo Finance
Spruce Biosciences Announces Launch of MPS3BStudy.com - Yahoo Finance
H.C. Wainwright reiterates Spruce Biosciences stock rating on BLA progress - Investing.com
Spruce’s successful FDA talks plant seeds for Q4 filing of ultra-rare disease drug - fiercebiotech.com
Spruce (SPRB) Q2 2026 Earnings: The Bottom-Line Figure Trails Its Comparison in the Latest Session; Reaction Snapshot: Shares Finish 0.14% Lower in the Current UpdateNon-GAAP Earnings - vinanet.vn
Spruce Biosciences receives $5.5M from patient advocacy groups By Investing.com - Investing.com Nigeria
Guggenheim lowers Spruce Biosciences stock price target to $104 By Investing.com - Investing.com South Africa
SPRB Maintained by Guggenheim -- Price Target Lowered to $104 - GuruFocus
Guggenheim lowers Spruce Biosciences stock price target to $104 - Investing.com
Spruce Biosciences (SPRB) Climbs 5.77% to $52.64 as Momentum Builds Toward $55.27 ResistanceBPI Reversal - vinanet.vn
Spruce Biosciences (NASDAQ:SPRB) Downgraded to Strong Sell Rating by Wall Street Zen - MarketBeat
OrbiMed discloses 7.3% ownership of Spruce Biosciences (SPRB) common stock - Stock Titan
Spruce Biosciences | SCHEDULE 13G: Others - Moomoo
Spruce Biosciences | SCHEDULE 13G/A: Others - Moomoo
Spruce Biosciences (SPRB): ADAR1, Schneeberger disclose 2.5% beneficial stake - Stock Titan
Citadel entities and Kenneth Griffin (SPRB) report 1.9% beneficial stake in Spruce - Stock Titan
Spruce Biosciences (SPRB) sees AWM Investment disclose 5.1% equity stake - Stock Titan
SPRB Maintained by Citizens -- Price Target Lowered to $144 - GuruFocus
Craig-Hallum Maintains Spruce Biosciences(SPRB.US) With Buy Rating, Maintains Target Price $140 - Moomoo
Spruce Biosciences (NASDAQ:SPRB) Given New $144.00 Price Target at Citizens Jmp - MarketBeat
Spruce Biosciences (SPRB) Rises 1.42% as Shares Approach Key Resistance at $49.42Extension Target - vinanet.vn
Citizens cuts Spruce Biosciences stock price target on share dilution By Investing.com - Investing.com Australia
Citizens cuts Spruce Biosciences stock price target on share dilution - Investing.com
Spruce Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Updates - biospace.com
Spruce Biosciences (NASDAQ:SPRB) Issues Quarterly Earnings Results, Misses Estimates By $0.89 EPS - MarketBeat
Spruce Biosciences Q2 Results: EPS Misses Estimate, Losses Widen 91% YoY - scanx.trade
Spruce Biosciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Form 8K Spruce Biosciences Inc For: 12 August By Investing.com - Investing.com South Africa
Spruce Biosciences, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Spruce Biosciences, Inc. (SPRB) Stock Price, News, Quote & History - Yahoo! Finance Canada
SPRUCE BIOSCIENCES, INC. 2Q 2026: Net loss $(16.2M), EPS $(6.68) — 10-Q Summary - TradingView
SPRB: TA-ERT BLA submission and confirmatory study set for Q4 2026, with strong cash reserves and new leadership - TradingView
Spruce Biosciences reports Q2 2026 net loss $16.2M, cash $96.3M; BLA for TA-ERT expected Q4 2026 - TradingView
Spruce Biosciences Q2 2026 Results: Expenses Rise Ahead of the TA-ERT Filing - TradingKey
SPRB: Q2 2026 net loss rose to $16.2M as R&D spending surged, with $96.3M in cash on hand - TradingView
Spruce Biosciences (SPRB) ramps TA-ERT spend while lifting cash to $96.3M - Stock Titan
Spruce Biosciences posts $16.2 million Q2 net loss - Quiver Quantitative
Spruce Biosciences Q2 net loss widens on higher expenses - TradingView
8-K: Spruce Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Updatesmoomoo - Moomoo
Spruce Biosciences (SPRB) doubles cash as TA-ERT BLA and $5.5M backing advance - Stock Titan
Spruce Biosciences receives $5.5M from patient advocacy groups - Investing.com
Cure Sanfilippo Foundation and National MPS Society Make $5.5 Million Strategic Investment in Spruce Biosciences - Yahoo Finance
Spruce Biosciences, Inc. announced that it has received $5.500192 million in funding - marketscreener.com
SPRB Stock Drops After Company Pushes Back Application Submission Timeline For Experimental Sanfilippo Syndrome Therapy - Stocktwits
Spruce Biosciences Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants - The National Law Review
Spruce Biosciences, Inc. announced that it expects to receive $5.500192 million in funding - marketscreener.com
Spruce Biosciences Inc Azioni (SPRB) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.04%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):